A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of:

* casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
* casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab in participants with ccRCC in the dose expansion stage
Clear Cell Renal Cell Carcinoma|Solid Tumors
DRUG: casdatifan|DRUG: Cabozantinib|DRUG: Zimberelimab
Number of participants with dose limiting toxicities (DLTs), Up to 4 months|Number of participants with adverse events (AEs), Up to 4 months
Objective Response Rate as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Up to 4 months|Plasma concentration of casdatifan, Up to 4 months|Area under the plasma concentration time curve (AUC) of casdatifan, Up to 4 months|Maximum Observed Plasma Concentration (Cmax) of casdatifan, Up to 4 months
The purpose of this study is to evaluate the safety and tolerability of:

* casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
* casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab in participants with ccRCC in the dose expansion stage